NewLink Genetics Corporation (NASDAQ:NLNK) Files An 8-K Other Events

NewLink Genetics Corporation (NASDAQ:NLNK) Files An 8-K Other Events
Item 8.01.Other Events.

Story continues below

On December 2, 2018, NewLink Genetics Corporation issued a press release titled "NewLink Genetics Presents Encouraging Updated Phase 1 Data with Indoximod Plus Chemotherapy in Frontline AML in an Oral Session at 2018 ASH Annual Meeting."

A copy of the press release is attached hereto as Exhibits 99.1 and is incorporated herein by reference.

Section9 – Financial Statements and Exhibits

Item 9.01.FinancialStatements and Exhibits.

(d) Exhibits.


NEWLINK GENETICS CORP Exhibit
EX-99.1 2 nlnk-20181203x8kxex991.htm PRESS RELEASE Exhibit Exhibit 99.1NewLink GeneticsPresents Encouraging Updated Phase 1 Data with Indoximod Plus Chemotherapy in Frontline AML in an Oral Session at 2018 ASH Annual Meeting –Updated Phase 1 data for indoximod plus standard-of-care chemotherapy in newly diagnosed AML show post-induction minimal residual disease (MRD) negativity rate of 86% and post-consolidation MRD negativity of 100%–Safety data from this study indicate the combination treatment regimen was well tolerated with no regimen limiting toxicities (RLTs) observedAmes,…
To view the full exhibit click here

About NewLink Genetics Corporation (NASDAQ:NLNK)

NewLink Genetics Corporation is a biopharmaceutical company focused on discovering, developing and commercializing immunotherapeutic products for cancer treatment. The Company’s portfolio includes biologic and small-molecule immunotherapy product candidates for a range of oncology indications. Its biologic product candidates are based on its HyperAcute immunotherapy technology platform, which is designed to stimulate the human immune system. Algenpantucel-L is its clinically advanced product candidate for patients with pancreatic cancer. Its additional HyperAcute cellular HyperAcute Cellular Immunotherapy product candidates in clinical development include tergenpumatucel-L and dorgenmeltucel-L for patients with advanced lung cancer and melanoma. It has two small-molecule product candidates in clinical development: GDC-0919 and indoximod. These product candidates are indoleamine-2, 3-dioxygenase (IDO) pathway inhibitors and focus on breaking the immune system’s tolerance to cancer.

An ad to help with our costs